Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 938-950

  Mathews, L R ^a,b   Lott, J M ^a   Isse, K ^a,c   Lesniak, A ^a,c   Landsittel, D ^a,c   Demetris, A J ^a,c   Sun, Y ^d   Mercer, D F ^d   Webber, S A ^e   Zeevi, A ^a,c   Fischer, R T ^d   Feingold, B ^f   Turnquist, H R ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; PROTEIN; SOLUBLE SUPPRESSOR OF TUMORIGENICITY 2; SUPPRESSOR OF TUMORIGENICITY 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; MESSENGER RNA;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANTIBODY MEDIATED REJECTION; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; INTESTINE TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SMALL BOWEL GRAFT REJECTION; ADOLESCENT; ADVERSE EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASES; INCIDENCE; INTESTINAL DISEASES; METABOLISM; PATHOLOGY; PENNSYLVANIA; POSTOPERATIVE COMPLICATION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRANSPLANTATION;

ADOLESCENT; BIOMARKERS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; INCIDENCE; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTESTINAL DISEASES; INTESTINE, SMALL; MALE; PENNSYLVANIA; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84959571725     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13542     Document Type: Article

References (50)

1. Lodhi SA, Lamb KE, Meier-Kriesche HU., Solid organ allograft survival improvement in the United States: The long-term does not mirror the dramatic short-term success. Am J Transplant 2011; 11: 1226-1235.
2. LaRosa C, Baluarte HJ, Meyers KE., Outcomes in pediatric solid-organ transplantation. Pediatr Transplant 2011; 15: 128-141.
3. Lund LH, Edwards LB, Kucheryavaya AY, et al., The Registry of the International Society for Heart and Lung Transplantation: Thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 951-964.
4. Dipchand AI, Kirk R, Edwards LB, et al., The Registry of the International Society for Heart and Lung Transplantation: Sixteenth official pediatric heart transplantation report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 979-988.
5. Evans RW, Williams GE, Baron HM, et al., The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant 2005; 5: 1553-1558.
6. Hamour IM, Burke MM, Bell AD, Panicker MG, Banerjee R, Banner NR., Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation 2008; 85: 969-974.
7. Kucirka LM, Maleszewski JJ, Segev DL, Halushka MK., Survey of North American pathologist practices regarding antibody-mediated rejection in cardiac transplant biopsies. Cardiovasc Pathol 2011; 20: 132-138.
8. Talmon G, El Behery R, Radio S, Fischer R, Shostrom V, Wisecarver J,. Crypt apoptotic count reproducibility in small bowel allograft biopsies. Int J Surg Pathol 2013; 21: 257-260.
9. Yang HM, Lai CK, Gjertson DW, et al., Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection ? Cardiovasc Pathol 2009; 18: 198-204.
10. Angelini A, Andersen CB, Bartoloni G, et al., A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection: The European experience. J Heart Lung Transplant 2011; 30: 1214-1220.
11. Schmitz J, Owyang A, Oldham E, et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
12. Liew FY, Pitman NI, McInnes IB., Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-110.
13. Liu Q, Turnquist HR., Implications for interleukin-33 in solid organ transplantation. Cytokine 2013; 62: 183-194.
14. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M., Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994; 13: 1176-1188.
15. Thomassen E, Kothny G, Haas S, et al., Role of cell type-specific promoters in the developmental regulation of T1, an interleukin 1 receptor homologue. Cell Growth Differentiation 1995; 6: 179-184.
16. Iwahana H, Yanagisawa K, Ito-Kosaka A, et al., Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999; 264: 397-406.
17. Lipsky BP, Toy DY, Swart DA, Smithgall MD, Smith D., Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol 2012; 42: 1863-1869.
18. Kumar S, Tzimas MN, Griswold DE, Young PR., Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997; 23: 474-478.
19. Weinberg EO, Shimpo M, De Keulenaer GW, et al., Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
20. Mildner M, Storka A, Lichtenauer M, et al., Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010; 87: 769-777.
21. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-1549.
22. Januzzi JL Jr, Peacock WF, Maisel AS, et al., Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50: 607-613.
23. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M., Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752-756.
24. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL., Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009; 2: 311-319.
25. Ky B, French B, McCloskey K, et al., High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180-187.
26. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al., Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009; 54: 2174-2179.
27. Sabatine MS, Morrow DA, Higgins LJ, et al., Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117: 1936-1944.
28. Shimpo M, Morrow DA, Weinberg EO, et al., Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
29. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT., Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721-726.
30. Pastorelli L, Garg RR, Hoang SB, et al., Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107: 8017-8022.
31. Vander Lugt MT, Braun TM, Hanash S, et al., ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529-539.
32. Isse K, Grama K, Abbott IM, et al., Adding value to liver (and allograft) biopsy evaluation using a combination of multiplex quantum dot immunostaining, high-resolution whole-slide digital imaging, and automated image analysis. Clin Liver Dis 2010; 14: 669-685.
33. Isse K, Lesniak A, Grama K, et al., Preexisting epithelial diversity in normal human livers: A tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology 2013; 57: 1632-1643.
34. Rabe-Hesketh S, Skrondal A., Multilevel and longitudinal modeling using Stata. 2nd ed. College Station, TX: Strata Press, 2008.
35. Turnquist HR, Zhao Z, Rosborough BR, et al., IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187: 4598-4610.
36. Gossett JG, Canter CE, Zheng J, et al., Decline in rejection in the first year after pediatric cardiac transplantation: A multi-institutional study. J Heart Lung Transplant 2010; 29: 625-632.
37. Pascual-Figal DA, Garrido IP, Blanco R, et al., Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg 2011; 92: 2118-2124.
38. Januzzi JL Jr,. ST2 as a cardiovascular risk biomarker: From the bench to the bedside. J Cardiovasc Transl Res 2013; 6: 493-500.
39. Beltran CJ, Nunez LE, Diaz-Jimenez D, et al., Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1097-1107.
40. Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T., Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010; 36: 630-637.
41. Ishikawa S, Shimizu M, Ueno K, Sugimoto N, Yachie A., Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine 2013; 62: 272-277.
42. Lo DJ, Kaplan B, Kirk AD., Biomarkers for kidney transplant rejection. Nat Rev Nephrol 2014; 10: 215-225.
43. Wu T, Abu-Elmagd K, Bond G, Nalesnik MA, Randhawa P, Demetris AJ., A schema for histologic grading of small intestine allograft acute rejection. Transplantation 2003; 75: 1241-1248.
44. Adeyi OA, Randhawa PA, Nalesnik MA, et al., Posttransplant adenoviral enteropathy in patients with small bowel transplantation. Arch Pathol Lab Med 2008; 132: 703-705.
45. Talmon GA., Histologic features of cytomegalovirus enteritis in small bowel allografts. Transplant Proc 2010; 42: 2671-2675.
46. Gleissner CA, Klingenberg R, Nottmeyer W, et al., Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 2003; 17: 284-291.
47. Mueller T, Jaffe AS., Soluble ST2-Analytical considerations. Am J Cardiol 2015; 115(7 Suppl): 8B-21B.
48. De Vlaminck I, Valantine HA, Snyder TM, et al., Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 2014; 6: 241ra277-241ra 277.
49. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al., Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725.
50. Bayes-Genis A, de Antonio M, Galán A, et al., Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012; 14: 32-38.